Altpep is a peptide-based platform used to diagnose and neutralize toxic precursors to amyloid diseases. AltPep approached IX with a wealth of clinical, research, and IP, but little experience in fundraising, investor relations, or business management. In just 3 months, IX was able to facilitate meetings with strategic investors and raise over $1M. IX created a sophisticated investor deck with a financial pro forma, effectively communicating the technicality and potential of the company. To date, AltPep has raised over 23.1M in Series A financing. Recently, AltPep received FDA Breakthrough Device Designation.